Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Ipratropium

Criteria

Inclusion Criteria:

• Patients of both gender older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease

• Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler